Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder

Carola Rong 1, Caroline Park 1,2, Joshua D. Rosenblat 1,3, Mehala Subramaniapillai 1,2, Hannah Zuckerman 1, Dominika Fus 1, Yena L. Lee 1,2, Zihang Pan 1,2, Elisa Brietzke 1,4, Rodrigo B. Mansur 1,3, Danielle S. Cha 1, Leanna M. W. Lui 1 and Roger S. McIntyre 1,2,3,5,*

1 Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, ON MT5 2S8, Canada; carola.rong@gmail.com (C.R.); caroline.park@mail.utoronto.ca (C.P.); joshua.rosenblat@uhn.ca (J.D.R.); mehala.subram@uhn.ca (M.S.); hannahzuckerman2@gmail.com (H.Z.); dominikafus@icloud.com (D.F.); yenalee.lee@mail.utoronto.ca (Y.L.L.); danny.pan@mail.utoronto.ca (Z.P.); elisabrietzke@hotmail.com (E.B.); rodrigomansur71@uol.com.br (R.B.M.); cha.danielle@gmail.com (D.S.C.); leanna.lui19@gmail.com (L.M.W.L.)
2 Institute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada
3 Department of Psychiatry, University of Toronto, Toronto, ON M5T 1R8, Canada
4 Department of Psychiatry, Federal University of São Paulo, São Paulo 05403-903, Brazil
5 Department of Pharmacology, University of Toronto, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada
* Correspondence: Roger.McIntyre@uhn.ca; Tel.: +416-603-5279; Fax: +416-603-5368

Received: 28 February 2018; Accepted: 12 April 2018; Published: 17 April 2018

Abstract: Objectives: Extant evidence indicates that ketamine exerts rapid antidepressant effects in treatment-resistant depressive (TRD) symptoms as a part of major depressive disorder (MDD) and bipolar disorder (BD). The identification of depressed sub-populations that are more likely to benefit from ketamine treatment remains a priority. In keeping with this view, the present narrative review aims to identify the pretreatment predictors of response to ketamine in TRD as part of MDD and BD. Method: Electronic search engines PubMed/MEDLINE, ClinicalTrials.gov, and Scopus were searched for relevant articles from inception to January 2018. The search term ketamine was cross-referenced with the terms depression, major depressive disorder, bipolar disorder, predictors, and response and/or remission. Results: Multiple baseline pretreatment predictors of response were identified, including clinical (i.e., Body Mass Index (BMI), history of suicide, family history of alcohol use disorder), peripheral biochemistry (i.e., adiponectin levels, vitamin B12 levels), polysomnography (abnormalities in delta sleep ratio), neurochemistry (i.e., glutamine/glutamate ratio), neuroimaging (i.e., anterior cingulate cortex activity), genetic variation (i.e., Val66Met BDNF allele), and cognitive functioning (i.e., processing speed). High BMI and a positive family history of alcohol use disorder were the most replicated predictors. Conclusions: A pheno-biotype of depression more, or less likely, to benefit with ketamine treatment is far from complete. Notwithstanding, metabolic-inflammatory alterations are emerging as possible pretreatment response predictors of depressive symptom improvement, most notably being cognitive impairment. Sophisticated data-driven computational methods that are iterative and agnostic are more likely to provide actionable baseline pretreatment predictive information.

Keywords: ketamine; depression; MDD; response; predictors; remission
1. Introduction

Major Depressive Disorder (MDD) is a highly prevalent, chronic, and disabling disorder that is affecting approximately 350 million individuals worldwide, with only one-third of affected individuals remitting with first-line antidepressant treatment [1]. Moreover, approximately one-third of individuals fail to achieve syndromal and functional recovery despite receiving multimodality treatment interventions [2]. A modifiable deficiency in the management of MDD is in reducing the time to onset of clinically significant improvement in symptoms with conventional treatment interventions (e.g., antidepressant medication). For example, it often requires approximately 4 to 8 weeks of treatment before clinically significant therapeutic improvements are observed [3]. This therapeutic inertia prolongs the patient-reported symptoms of depression, leaves individuals at a greater risk for suicidality, and increases the economic costs (direct and indirect) that are related to MDD [4].

Convergent evidence indicates that subanesthetic doses of ketamine, which is a dissociative anesthetic that antagonizes glutamatergic N-methyl-D-aspartate (NMDA) receptors, has rapid-onset antidepressant effects in subpopulations with MDD and bipolar disorder (BD) that do not sufficiently respond to conventional antidepressant therapies [5]. In addition to antidepressant effects, anti-suicide effects have also been reported with ketamine, independent of its salutary effects on total depressive symptom severity [6–8]. It has been reported that the magnitude of therapeutic benefits that are associated with ketamine treatment in treatment-resistant depression (TRD) is comparable to the therapeutic benefits that are associated with electroconvulsive therapy [9]. However, the current evidence is not sufficient to recommend ketamine as an antidepressant, as ketamine may carry the risk of diversion and misuse. The medical communities should conduct more research and be more critical of the evidence provided by ketamine trials [10].

The mechanism of action of ketamine has not yet been fully characterized, but is hypothesized to involve downstream actions on multiple effector systems, including, but not limited to, the monoamine system, the opioid system, the gamma aminobutyric acid (GABA)/glutamate system, signal transduction cascades (i.e., mTor, rapamycin), cellular proliferation, and neuroplasticity-promoting intracellular cascades [11,12]. A single subanesthetic (0.5 mg/kg) intravenous (IV) infusion of ketamine over 40 min has been demonstrated to result in significant improvements of depressive symptoms within 4 h, and lasting up to seven days [5]. After infusion of ketamine, the response rate at 6 h is 54%; day 1 is 71%; and, day 3 is 54% [13]. The mean duration to relapse of another depressive episode is 17.2 days after a single infusion of ketamine. The antidepressant effects of ketamine in treatment-resistant mood populations have been supported by multiple lines of evidence, including original research, systematic reviews, and meta-analyses [14].

A primary clinical concern related to the therapeutic use of ketamine for TRD is tolerability (e.g., dissociative phenomena, vasomotor effects) and safety (e.g., CNS effects) concerns, with both short- and long-term administration. There is a lack of studies evaluating the systemic side effects of repeated IV ketamine infusion, including cystitis and urinary incontinence [15]. The need for IV infusion and post-administration surveillance with IV ketamine introduces complexities and costs that are inherent to ketamine treatment [16]. Hence, the identification of pretreatment predictors of safety, tolerability, and efficacy in response to IV ketamine would provide the opportunity to empirically select (and exclude) subpopulations with TRD who are more likely (or less likely) to benefit from treatment. In addition to improving therapeutic response prediction, delineating subpopulations with TRD that are more likely to benefit from ketamine treatment has implications for cost-modeling cost-effectiveness analyses.

Herein, we aim to identify and summarize pretreatment clinical and biological predictors of successful response to IV ketamine infusion in adults with TRD as part of MDD and BD. We purposefully delimit our focus to reports evaluating IV ketamine infusion, as this is the most commonly reported delivery method in the biomedical literature.
2. Methods

An electronic literature search was conducted using the following databases: PubMed/MEDLINE, ClinicalTrials.gov, and Scopus from inception to January 2018. The search term ketamine was cross-referenced with the terms depression, major depressive disorder, bipolar disorder, predictors, and response and/or remission. All of the identified articles were screened for inclusion in the present review based on their title and abstract. Search results that were irrelevant to the scope of this manuscript were excluded from further review. Articles were manually reviewed with an aim to identify variables that were of focus in the review herein. Bibliographies were also manually searched to identify additional pertinent studies. Inclusion criteria were established prior to article review and were as follows:

1. adult subjects (ages 18–65) with a diagnosis of MDD or BD and/or TRD as defined by the Diagnostic and Statistical Manual (DSM);
2. study was an intervention trial of IV ketamine infusion; and,
3. depression severity was assessed before and after ketamine infusion, and reported using standardized and validated depression rating scales.

Exclusion criteria were:

1. unpublished data;
2. preclinical studies; and,
3. reports on duplicated datasets.

3. Results

The original search yielded a total of 582 records; 511 records were excluded that were not human clinical trials (i.e., preclinical trials). After the screening of titles and abstracts, 12 studies evaluating response to ketamine in adults with MDD or BD and/or TRD were included in the review; nine studies were included via electronic search; and, three studies were included via manual search. Results from the literature search are summarized in Table 1.

| Predictors of Ketamine Response | Studies | Number of Subjects |
|--------------------------------|---------|--------------------|
| Sociodemographic               | None    | None               |
| Clinical                        |         |                    |
| Positive family history of alcohol use disorder in a first-degree relative (FHP) | Phelps et al. 2009 [17]. | MDD (n = 26) |
|                                |         | Luckenbaugh et al. 2012 [18]. | MDD and BD (n = 33) |
|                                |         | Niciu et al. 2014 [19]. | MDD (n = 52) |
| High BMI                       |         | Niciu et al. 2014 [19]. | MDD (n = 108) |
| No prior suicide history        |         | Niciu et al. 2014 [19]. | MDD (n = 108) |
| Peripheral biochemistry         |         |                    |
| Low baseline adiponectin levels | Machado-Vieira et al. 2017 [20]. | MDD (n = 49) BD (n = 31) |
| High baseline peripheral B12 level | Permuda-Osip et al. 2013 [21]. | BD (n = 20) |
| Polysomnography                 |         |                    |
| Low baseline delta sleep ratio  | Duncan et al. 2013 [22]. | MDD (n = 30) |
| Neurochemistry                  |         |                    |
| Low Glx/glutamate ratio         | Salvador et al. 2012 [23]. | MDD (n = 14) |
| Neuroimaging                    |         |                    |
| Increased pretreatment anterior cingulate cortex activity | Salvador et al. 2009 [24]. | MDD (n = 11) HC (n = 11) |
| Genetics                        |         |                    |
| Val66Met BDNF allele            | Laje et al. 2012 [25]. | MDD (n = 62) |
| Cognition                       |         |                    |
| Poor baseline neurocognitive score | Murrough et al. 2013 [26]. | MDD (n = 25) |

3.1. Sociodemographic Variables

No sociodemographic factors were found to robustly predict patient response to ketamine.
3.2. Clinical Variables

A positive family history of alcohol use disorder (FHP) was associated with a greater probability of response to ketamine infusion in individuals with MDD and BD when compared to healthy controls, as evidenced by the change in total Montgomery-Asberg Depression Scale (MADRS) score from baseline to endpoint [17,18]. Subjects with a positive family history of alcohol use disorder exhibited greater improvement in Hamilton Depression Rating Scale (HDRS) score at one-day and seven-days post-infusion, but not at 230 min post-infusion. A study that was conducted by Niciu et al. (2014) expanded on this finding by demonstrating that the antidepressant effects of ketamine could be sustained for up to four weeks in subjects with a FHP [19].

In addition to FHP, a separate post-hoc analysis that was conducted by Niciu et al. (2014) reported that a symptomatic improvement in MDD and BD subjects (n = 108) was moderated by body mass index (BMI) and a prior history of suicide attempts. Specifically, higher pretreatment BMI was correlated with greater improvement in total HDRS score at 230-min and one-day post-infusion, but not at seven-days post-infusion. A meta-analysis has established a positive association between obesity and early-onset depression [27]. Epidemiological studies found that increased BMI was associated with depressive symptoms in adults [28]. Stressors can cause down-regulation of leptin signalling, resulting in poor appetite control [29].

In addition, individuals without a history of suicide attempts had greater improvement in HDRS score at seven-days post-infusion, but not at earlier time points. Moreover, BMI was associated with acute symptomatic improvement, while FHP and no prior history of suicide attempts were associated with a sustained antidepressant response to ketamine [30]. It was also reported that while higher BMI as a pretreatment response predictor to ketamine might possibly be an epiphenomenon of a relatively higher administered dose of ketamine in this subpopulation.

3.3. Peripheral Biomarkers

Machado-Vieira et al. (2017) sought to identify specific adipokines that moderate the relationship between IV ketamine response, anthropometrics (i.e., BMI), and depressive symptomatology. They observed that low pretreatment plasma adiponectin levels predicted rapid response to ketamine [20]. Adiponectin is an adipokine (i.e., cytokine secreted by adipose tissue) that is known to exert anti-inflammatory and insulin-sensitizing effects. The observation of pretreatment pro-inflammatory balance may be a potential predictor of an antidepressant response. The levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor (TNF-α) have been reported to be higher in MDD subjects than controls [31]. Conventional antidepressants (e.g., fluoxetine) have been found to reduce both central and peripheral levels of the pro-inflammatory cytokine interleukin-1 beta (IL-β) in the alleviation of depressive symptoms [32]. Other treatments with antidepressant properties have also been reported with mechanistically dissimilar treatments (e.g., omega 3 fatty acids, L-methylfolate) [33].

In addition to pretreatment pro-inflammatory cytokines potentially moderating response to ketamine, preliminary evidence indicates that circulating vitamin B12 levels may affect the treatment outcomes with ketamine [34]. Previous reports indicate that higher levels of circulating vitamin B12 are associated with a greater probability of response to conventional antidepressants [35].

To contextualize the foregoing results, a single small study with 20 subjects identified vitamin B12 levels were cross-sectionally associated with bipolar depression. Specifically, ketamine treatment “responders” had higher levels of circulating vitamin B12 when compared to “non-responders”, where “responders” were subjects with a 50% or greater reduction of HDRS, as compared to baseline, on the seventh day after infusion. This result is consistent with studies showing that higher levels of vitamin B12 are positively correlated with the conventional antidepressant response [21,35].
3.4. Polysomnography

Slow wave sleep has consistently been reported to be decreased in individuals with MDD and BD [36]. Delta sleep ratio (DSR) is defined as the ratio of slow wave activity between the first two non-REM sleep episodes, and it is reported to be relatively lower in MDD patients than in healthy controls [37]. In a study by Duncan et al. (2013), it was observed in 30 subjects with MDD that low pretreatment DSR was associated with a greater improvement in total depressive symptom severity, whereas high pretreatment DSR predicted a less favourable response to IV ketamine treatment [22].

3.5. Neurochemistry Variables

Abnormalities in amino acid neurotransmitter systems are postulated to play a critical role in the pathoetiology of MDD [38]. Stress-induced depression and cognitive impairment have been found to be associated with the reduced expression of the gamma-aminobutyric acid (GABA) receptors in the brain [39].

Using proton magnetic resonance spectroscopy (1H-MRS), Salvadore et al. (2012) measured levels of the amino acid neurotransmitters gamma aminobutyric acid (GABA), glutamate, and Glx/glutamate (a surrogate marker of glutamine), in the ventromedial and the dorsomedial/dorsal anterolateral prefrontal cortex before and after IV ketamine treatment in subjects with MDD (n = 14). Following ketamine infusion, depressive symptoms significantly improved after 230 min, as assessed by the changes in the mean MADRS score. The authors reported that while pretreatment GABA and glutamate did not correlate with an improvement of depressive symptoms, pretreatment Glx/glutamate ratio was found to be significantly and inversely correlated with the symptomatic improvement with ketamine [23].

3.6. Noninvasive Functional Neuroimaging

Salvadore et al. (2009) evaluated the effect of IV ketamine on anterior cingulate cortical (ACC) activity in response to an emotional stimulus in subjects with MDD (n = 11) versus healthy controls (n = 11). Subjects with MDD exhibited exaggerated ACC activity, which was positively and significantly correlated with a rapid antidepressant response to IV ketamine [24]. The foregoing results suggest that IV ketamine treatment may target neural structures subserving affective processing and cognitive-emotional reactivity. It is hypothesized that these observed effects of ketamine on neural structures and circuits that are relevant to psychopathology in mood disorders is principally mediated by ketamine-induced effects on AMPA-mediated synaptic plasticity [40].

3.7. Genetics

Central and peripheral brain derived neurotrophic factor (BDNF) levels are reported to be decreased in individuals with MDD and BD, and are positively correlated with the conventional antidepressant treatment response [41]. In accordance with this, the BDNF Val66Met single nucleotide polymorphism (SNP) has been reported to be associated with an impaired function of BDNF activity in the human brain [42]. Laje et al. (2012) investigated whether the Val66Met SNP was associated with ketamine treatment response in patients with MDD. They reported that the overall mean change in HDRS score from baseline to endpoint was significantly lower in Met carriers when compared to Val carriers. This observation suggests an increased likelihood of response to IV ketamine in depressed individuals carrying the Val/Val BDNF allele at rs6265e [25].

3.8. Cognitive Function

Neurocognitive impairment in individuals with MDD and BD is a highly replicated finding and enduring abnormality during and between episodes [43]. Specific symptoms of depression, such as insomnia, are associated with neurocognitive impairment [44]. In addition to serving as a proximate mediator of functional outcome in mood disorders, early improvement in cognitive
performance has been suggested as a predictor of treatment response [45]. Preliminary evidence suggests that pretreatment cognitive performance may influence the overall treatment response to ketamine. For example, Murrough et al. (2013) assessed baseline neurocognitive functioning in subjects (n = 25) with TRD, using a comprehensive battery (estimated premorbid IQ, current IQ, and tests from the MATRICS battery). At 40 min post-infusion, the participants repeated a subset of the neurocognitive tests, while a change in depression severity was measured using MADRS, with response status being defined as a ≥50% reduction in MADRS score at 24 h relative to baseline. The authors of the study reported that lower levels of baseline neurocognitive performance (in particular processing speed) in individuals with TRD are associated with an increased antidepressant response rate to ketamine [26].

Of note, a separate hypothesis has been proffered which suggests that the pro-cognitive effects of ketamine mediate the anti-suicidal effects that are associated with ketamine treatment in adults with mood disorders [6].

4. Discussion

There is an urgent need to identify predictors of response to psychotropic medications in subpopulations with mood disorders. When considering IV ketamine for TRD, the safety, tolerability, and costs associated with this treatment further amplify the need to identify reliable predictors of ketamine response. The identification of pretreatment predictors would guide clinicians and provide decision support as it regards the selection and sequencing of ketamine treatment in a cost-effective manner. Mechanistically, it may be surmised that the variables that predict the ketamine response reflect the putative mechanism of action of ketamine (e.g., inflammatory, metabolic, glutamatergic, and monoaminergic actions). For example, disturbances in the inflammation in the human central nervous system, and the associated glutamatergic dysregulation, are implicated as mechanistically relevant to mood disorders [46]). As ketamine has direct and indirect actions on glutamatergic signalling and inflammation, it is not surprising that pretreatment inflammatory and/or glutamatergic biomarkers may predict ketamine response.

The available evidence indicates that ketamine exerts rapid and robust antidepressant effects in patients with TRD. Herein, we identified several preliminary variables that are associated with a positive response to IV ketamine treatment. The observation that pretreatment inflammatory markers may have predictive potential coheres with other lines of evidence, indicating that a cross talk exists between inflammatory and glutamatergic systems [47]. Moreover, it has been further conjectured that individuals with disturbances in central amino acid neurotransmitters (i.e., GABA, glutamate) and/or pro-inflammatory cytokines (e.g., reward processing abnormalities) may particularly benefit from ketamine treatment. Ketamine has also been hypothesized to engage neuroplasticity processes; this observation would be in keeping with the moderational effects of the BDNF Val66Met SNP on the treatment response, as BDNF is known to be highly involved in neuroplastic processes within the brain.

Antidepressant treatment response is highly variable among patients, which may reflect the differences in the underlying pathophysiology, genetic architecture, clinical features, etc. With the identification of novel pretreatment predictors (i.e., phenotypic and biological variables) of response, there will be an opportunity for personalized healthcare and significantly improved clinical outcomes for patients. The absence of long-term clinical data, concerns related to the safety, and the tolerability of short- and long-term ketamine exposure, as well as the expense of IV administration invite the need for careful patient selection and treatment candidacy. Another important consideration is the effect size (i.e., predictive value) of individual pretreatment predictors, which would help to stratify patients for treatment accordingly.

The current review has several significant limitations. The most significant limitation was the small sample size of many of the studies that were included in the review. Another limitation is the heterogeneity of the study designs. Other limitations include lack of randomization, open-label trials, and lack of healthy control groups. Currently, no single pretreatment variable has been able to
demonstrate a robust prediction for any antidepressant treatment response in MDD or BD. Instead, a combination of phenotypic (e.g., sociodemographic, clinical) and biological (e.g., neuroimaging, genetic) predictor variables will be necessary to identify patients who will be more likely to respond to ketamine. Endeavors are currently underway to identify the predictors of response to antidepressant treatment broadly, including, but not limited to, ketamine. It could be conjectured that machine learning techniques or capabilities may more likely be able to refine the phenotype that is most likely to benefit or not benefit from TRD therapy. It would be especially interesting to identify the subdomain response predictors e.g., improvements in cognitive measures and reward measures. Furthermore, there is a repository of studies evaluating ketamine studies on psychosocial and workplace function, consequently, identifying the predictors of response as defined by functional improvement and/or other patient reported outcomes (PROs) is an additional research vista. Previous epidemiological studies have found that the combination of having a history of unemployment and anticipated job insecurity increased the risk of developing depression [48]. Conventional antidepressants improve workplace functioning in patients that are suffering from MDD, and further studies on the effects of ketamine on workplace functioning is warranted [49].

5. Conclusions

Herein, we identified several putative pretreatments that may predict the antidepressant response to IV ketamine (see Table 1). Of the foregoing variables, the most replicated are BMI and FHP. A phenotypic response pattern to ketamine treatment for TRD is far from complete. Notwithstanding, disparate variables that are indicative of illness complexity emerge, with indirect evidence suggesting metabolic inflammatory alterations as pretreatment response prediction and cognitive impairment. Sophisticated data-driven computational methods that are iterative and agnostic are more likely to provide actionable baseline pretreatment prediction information.

Author Contributions: C.R. and R.S.M. conceived and wrote the paper. C.P., J.D.R., M.S., H.Z., D.F., Y.L.L., Z.P., E.B., R.B.M., D.S.C. and L.M.W.L. edited the paper.

Conflicts of Interest: R.S.M. has received speaking fees from Allergan, AstraZeneca, Bristol-Meyers, Janssen-Ortho, Lundbeck, Otsuka, Purdue, Pfizer, Shire, Sunovion, Neurocrine and Takeda. The other authors report no potential conflict of interest.

References

1. WHO | Depression. World Health Organization. February 2017. Available online: http://www.who.int/mediacentre/factsheets/fs369/en/ (accessed on 15 April 2016).
2. Ishak, W.W.; Greenberg, J.M.; Cohen, R.M. Predicting Relapse in Major Depressive Disorder Using Patient-Reported Outcomes of Depressive Symptom Severity, Functioning, and Quality of Life in the Individual Burden of Illness Index for Depression (IBI-D). J. Affect. Disord. 2013, 151, 59–65. [CrossRef] [PubMed]
3. Berton, O.; Nestler, E.J. New Approaches to Antidepressant Drug Discovery: Beyond Monoamines. Nat. Rev. Neurosci. 2006, 7, 137–151. [CrossRef] [PubMed]
4. Kleine-Budde, K.; Müller, R.; Kawohl, W.; Bramesfeld, A.; Moock, J.; Rössler, W. The Cost of Depression—A Cost Analysis from a Large Database. J. Affect. Disord. 2013, 147, 137–143. [CrossRef] [PubMed]
5. Coyle, C.M.; Laws, K.R. The Use of Ketamine as an Antidepressant: A Systematic Review and Meta-Analysis. Hum. Psychopharmacol. Clin. Exp. 2015, 30, 152–163. [CrossRef] [PubMed]
6. Lee, Y.; Syeda, K.; Maruschak, N.A.; Cha, D.S.; Mansur, R.B.; Wium-Andersen, I.K.; Woldeyohannes, H.O.; Rosenblat, J.D.; McIntyre, R.S. A New Perspective on the Anti-Suicide Effects With Ketamine Treatment. J. Clin. Psychopharmacol. 2016, 36, 50–56. [CrossRef] [PubMed]
7. Wilkinson, S.T.; Ballard, E.D.; Bloch, M.H.; Mathew, S.J.; Murrough, J.W.; Feder, A.; Sos, P.; Wang, G.; Zarate, C.A., Jr.; Sanacora, G. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am. J. Psychiatry 2018, 175, 150–158. [CrossRef] [PubMed]
8. Zhang, M.W.B.; Ho, R. Controversies of the Effect of Ketamine on Cognition. *Front. Psychiatry* Front. Res. Found. 2016, 7, 47. [CrossRef] [PubMed]

9. HSR Project Search System: View HSRProject Record. n.d. Available online: https://wwwcf.nlm.nih.gov/hsr_project/view_hsrproj_record.cfm?NLMUNIQUE_ID=20164159 (accessed on 28 February 2018).

10. Ho, R.C.M.; Zhang, M.W. Ketamine as a Rapid Antidepressant: The Debate and Implications. *BJPsych Adv.* 2016, 22, 222–233. [CrossRef]

11. Andrade, C. Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action. *J. Clin. Psychiatry* 2017, 78, e415–e419. [CrossRef] [PubMed]

12. Naughton, M.; Clarke, G.; O’Leary, O.F.; Cryan, J.F.; Dinan, T.G. A Review of Ketamine in Affective Disorders: Current Evidence of Clinical Efficacy, Limitations of Use and Pre-Clinical Evidence on Proposed Mechanisms of Action. *J. Affect. Disord.* 2014, 156, 24–35. [CrossRef] [PubMed]

13. Zhang, M.W.; Harris, K.M.; Ho, R.C. Is off-Label Repeat Prescription of Ketamine as a Rapid Antidepressant Safe? Controversies, Ethical Concerns, and Legal Implications. *BMJ* 2015, 351, h4467. [CrossRef] [PubMed]

14. Kishimoto, T.; Chawla, J.M.; Hagi, K.; Zarate, C.A.; Kane, J.M.; Bauer, M.; Correll, C.U. Single-Dose Infusion Ketamine and Non-Ketamine N-Methyl-D-Aspartate Receptor Antagonists for Unipolar and Bipolar Depression: A Meta-Analysis of Efficacy, Safety and Time Trajectories. *Psychol. Med.* 2016, 46, 1459–1472. [CrossRef] [PubMed]

15. Zhang, M.W.B.; Ho, R.C.M. Ketamine’s Potential as a Rapid Antidepressant Was Overplayed. *BMJ* 2015, 351, h4467. [CrossRef] [PubMed]

16. Andrade, C. Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency? *J. Clin. Psychiatry* 2017, 78, e852–e857. [CrossRef] [PubMed]

17. Phelps, L.E.; Brutsche, N.; Moral, J.R.; Luckenbaugh, D.A.; Manji, H.K.; Zarate, C.A. Family History of Alcohol Dependence and Initial Antidepressant Response to an N-Methyl-D-Aspartate Antagonist. *Biol. Psychiatry* 2009, 65, 181–184. [CrossRef] [PubMed]

18. Luckenbaugh, D.A.; Ibrahim, L.; Brutsche, N.; Franco-Chaves, J.; Mathews, D.; Marquardt, C.A.; Cassarly, C.; Zarate, C.A. Family History of Alcohol Dependence and Antidepressant Response to an N-Methyl-D-Aspartate Antagonist in Bipolar Depression. *Bipolar Disord.* 2012, 14, 880–887. [CrossRef] [PubMed]

19. Niciu, M.J.; Luckenbaugh, D.A.; Ionescu, D.F.; Richards, E.M.; Voort, J.L.V.; Ballard, E.D.; Brutsche, N.E.; Furey, M.L.; Zarate, C.A., Jr. Ketamine’s Antidepressant Efficacy Is Extended for at Least Four Weeks in Subjects with a Family History of an Alcohol Use Disorder. *Int. J. Neuropsychopharmacol. Off. Sci. J. Coll. Int. Neuropsychopharmacol.* 2014, 18. [CrossRef] [PubMed]

20. Machado-Vieira, R.; Gold, P.W.; Luckenbaugh, D.A.; Ballard, E.D.; Richards, E.M.; Henter, I.D.; de Sousa, R.T.; Niciu, M.J.; Yuan, P.; Zarate, C.A., Jr. The Role of Adipokines in the Rapid Antidepressant Effects of Ketamine. *Mol. Psychiatry* 2017, 22, 127–133. [CrossRef] [PubMed]

21. Permoda-Osip, A.; Dorszewska, J.; Bartkowska-Sniatkowska, A.; Chlopocka-Wozniak, M.; Rybakowski, J.K. Vitamin B12 Level May Be Related to the Efficacy of Single Ketamine Infusion in Bipolar Depression. *Pharmacopsychiatry* 2013, 46, 227–228. [CrossRef] [PubMed]

22. Duncan, W.C., Jr.; Selter, J.; Brutsche, N.; Sarasso, S.; Zarate, C.A., Jr. Baseline Delta Sleep Ratio Predicts Acute Ketamine Mood Response in Major Depressive Disorder. *J. Affect. Disord.* 2013, 145, 115–119. [CrossRef] [PubMed]

23. Salvadore, G.; van der Veen, J.W.; Zhang, Y.; Marenco, S.; Machado-Vieira, R.; Baumann, J.; Ibrahim, L.A.; Luckenbaugh, D.A.; Shen, J.; Drevets, W.C.; et al. An Investigation of Amino-Acid Neurotransmitters as Potential Predictors of Clinical Improvement to Ketamine in Depression. *Int. J. Neuropsychopharmacol. Off. Sci. J. Coll. Int. Neuropsychopharmacol.* 2012, 15, 1063–1072. [CrossRef] [PubMed]

24. Salvadore, G.; Cornwell, B.R.; Colon-Rosario, V.; Coppola, R.; Grillon, C.; Zarate, C.A., Jr.; Manji, H.K. Increased Anterior Cingulate Cortical Activity in Response to Fearful Faces: A Neurophysiological Biomarker That Predicts Rapid Antidepressant Response to Ketamine. *Biol. Psychiatry* 2009, 65, 289–295. [CrossRef] [PubMed]
25. Laje, G.; Lally, N.; Mathews, D.; Brutsche, N.; Chereminski, A.; Akula, N.; Kelmendi, B.; Simen, A.; McMahon, F.J.; Sanacora, G.; et al. Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients. *Biol Psychiatry* 2012, 72, e27–e28. [CrossRef] [PubMed]

26. Murrough, J.W.; Wan, L.B.; Iacoviello, B.; Collins, K.A.; Solon, C.; Glicksberg, B.; Perez, A.M.; Mathew, S.J.; Charney, D.S.; Iosifescu, D.V.; et al. Neurocognitive Effects of Ketamine in Treatment-Resistant Major Depression: Association with Antidepressant Response. *Psychopharmacology* 2013. [CrossRef] [PubMed]

27. Quek, Y.-H.; Tam, W.W.S.; Zhang, M.W.B.; Ho, R.C.M. Exploring the Association between Childhood and Adolescent Obesity and Depression: A Meta-Analysis. *Obes. Rev. Off. J. Int. Assoc. Study Obes.* 2017, 18, 742–754. [CrossRef] [PubMed]

28. Hwang, W.J.; Kim, J.A.; Rankin, S.H. Depressive Symptom and Related Factors: A Cross-Sectional Study of Korean Female Workers Working at Traditional Markets. *Int. J. Environ. Res. Public Health* 2017, 14. [CrossRef] [PubMed]

29. Yang, J.L.; Liu, D.X.; Jiang, H.; Pan, F.; Ho, C.S.; Ho, R.C. The Effects of High-Fat-Diet Combined with Chronic Unpredictable Mild Stress on Depression-like Behavior and Leptin/LepRb in Male Rats. *Sci. Rep.* 2016, 6, 35239. [CrossRef] [PubMed]

30. Niciu, M.J.; Luckenbaugh, D.A.; Ionescu, D.F.; Guevara, S.; Machado-Vieira, R.; Richards, E.M.; Brutsche, N.E.; Nolan, N.M.; Zarate, C.A., Jr. Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression. *J. Clin. Psychiatry* 2014, 75, e417–e423. [CrossRef] [PubMed]

31. Liu, Y.; Ho, R.C.M.; Mak, A. Interleukin (IL)–6, Tumour Necrosis Factor Alpha (TNF-α) and Soluble Interleukin-2 Receptors (sIL-2R) Are Elevated in Patients with Major Depressive Disorder: A Meta-Analysis and Meta-Regression. *J. Affect. Disord.* 2012, 139, 230–239. [CrossRef] [PubMed]

32. Lu, Y.; Ho, C.S.; Liu, X.; Chua, A.N.; Wang, W.; McIntyre, R.S.; Ho, R.C. Chronic Administration of Fluoxetine and pro-Inflammatory Cytokine Change in a Rat Model of Depression. *PLoS ONE* 2017, 12, e0186700. [CrossRef] [PubMed]

33. Shelton, R.C.; Pencina, M.J.; Barrentine, L.W.; Ruiz, J.A.; Fava, M.; Zajecka, J.M.; Papakostas, G.I. Association of Obesity and Inflammatory Marker Levels on Treatment Outcome: Results from a Double-Blind, Randomized Study of Adjunctive l-Methylfolate Calcium in Patients with MDD Who Are Inadequate Responders to SSRIs. *J. Clin. Psychiatry* 2015, 76, 1635–1641. [CrossRef] [PubMed]

34. Wang, N.; Yu, H.-Y.; Shen, X.-F.; Gao, Z.-Q.; Yang, C.; Yang, J.-J.; Zhang, G.-F. The Rapid Antidepressant Effect of Ketamine in Rats Is Associated with down-Regulation of pro-Inflammatory Cytokines in the Hippocampus. * Upsala J. Med. Sci.* 2015, 120, 241–248. [CrossRef] [PubMed]

35. Hintikka, J.; Tolmunen, T.; Tanskanen, A.; Viinamäki, H. High Vitamin B12 Level and Good Treatment Outcome May Be Associated in Major Depressive Disorder. *BMC Psychiatry* 2003, 3. [CrossRef] [PubMed]

36. Kudlow, P.A.; Cha, D.S.; Lam, R.W.; McIntyre, R.S. Sleep Architecture Variation: A Mediator of Metabolic Disturbance in Individuals with Major Depressive Disorder. *Sleep Med.* 2013, 14, 943–949. [CrossRef] [PubMed]

37. Germain, A.; Nofzinger, E.A.; Kupfer, D.J.; Buysse, D.J. Neurobiology of Non-REM Sleep in Depression: Further Evidence for Hypofrontality and Thalamic Dysregulation. *Am. J. Psychiatry* 2004, 161, 1856–1863. [CrossRef] [PubMed]

38. Skolnick, P. Modulation of Glutamate Receptors: Strategies for the Development of Novel Antidepressants. *Amino Acids* 2002, 23, 153–159. [CrossRef] [PubMed]

39. Lu, C.Y.; Liu, D.X.; Jiang, H.; Pan, F.; Ho, C.S.H.; Ho, R.C.M. Effects of Traumatic Stress Induced in the Juvenile Period on the Expression of Gamma-Aminobutyric Acid Receptor Type A Subunits in Adult Rat Brain. *Neural Plasticity* 2017, 2017, 5715816. [CrossRef] [PubMed]

40. Sanacora, G.; Zarate, C.A.; Krystal, J.H.; Manji, H.K. Targeting the Glutamatergic System to Develop Novel, Improved Therapeutics for Mood Disorders. *Nat. Rev. Drug Discov.* 2008, 7, 426–437. [CrossRef] [PubMed]

41. Lee, B.-H.; Kim, Y.-K. The Roles of BDNF in the Pathophysiology of Major Depression and in Antidepressant Treatment. *Psychiatry Investig.* 2010, 7, 231–235. [CrossRef] [PubMed]

42. Liu, R.-J.; Lee, F.S.; Li, X.Y.; Bambico, F.; Duman, R.S.; Aghajanian, G.K. Brain-Derived Neurotrophic Factor Val66Met Allele Impairs Basal and Ketamine-Stimulated Synaptogenesis in Prefrontal Cortex. *Biol. Psychiatry* 2012, 71, 996–1005. [CrossRef] [PubMed]
43. McIntyre, R.S.; Cha, D.S.; Soczynska, J.K.; Woldeyohannes, H.O.; Gallaugher, L.A.; Kudlow, P.; Alsuwaidan, M.; Baskaran, A. Cognitive Deficits and Functional Outcomes in Major Depressive Disorder: Determinants, Substrates, and Treatment Interventions. *Depress. Anxiety* 2013, 30, 515–527. [CrossRef] [PubMed]

44. Ling, A.; Lim, M.L.; Gwee, X.; Ho, R.C.M.; Collinson, S.L.; Ng, T.-P. Insomnia and Daytime Neuropsychological Test Performance in Older Adults. *Sleep Med.* 2016, 17, 7–12. [CrossRef] [PubMed]

45. Harmer, C.J.; O’Sullivan, U.; Favaron, E.; Massey-Chase, R.; Ayres, R.; Reinecke, A.; Goodwin, G.M.; Cowen, P. Effect of Acute Antidepressant Administration on Negative Affective Bias in Depressed Patients. *Am. J. Psychiatry* 2009, 166, 1178–1184. [CrossRef] [PubMed]

46. Rosenblat, J.D.; Cha, D.S.; Mansur, R.B.; McIntyre, R.S. Inflamed Moods: A Review of the Interactions between Inflammation and Mood Disorders. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 2014, 53, 23–34. [CrossRef] [PubMed]

47. Miller, A.H. Conceptual Confluence: The Kynurenine Pathway as a Common Target for Ketamine and the Convergence of the Inflammation and Glutamate Hypotheses of Depression. *Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol.* 2013, 38, 1607–1608. [CrossRef] [PubMed]

48. Wege, N.; Angerer, P.; Li, J. Effects of Lifetime Unemployment Experience and Job Insecurity on Two-Year Risk of Physician-Diagnosed Incident Depression in the German Working Population. *Int. J. Environ. Res. Public Health* 2017, 14. [CrossRef] [PubMed]

49. Lee, Y.; Rosenblat, J.D.; Lee, J.; Carmona, N.E.; Subramaniapillai, M.; Shekotikhina, M.; Mansur, R.B.; Brietzke, E.; Lee, J.-H.; Ho, R.C.; et al. Efficacy of Antidepressants on Measures of Workplace Functioning in Major Depressive Disorder: A Systematic Review. *J. Affect. Disord.* 2018, 227, 406–415. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).